HealthcareServices

Onychomycosis Market Future Outlook: Strong Growth Expected Toward $5.08 Billion by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the onychomycosis market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Onychomycosis Market?_x000D_

The onychomycosis market has experienced substantial growth in recent years. It is forecast to grow from $3.81 billion in 2025 to $4.03 billion in 2026, at a compound annual growth rate (CAGR) of 5.7%. The market’s development in the past can be linked to factors such as the high occurrence of onychomycosis, limited access to advanced antifungal medications, an increase in fungal nail infections due to an aging demographic, rising awareness among dermatologists, and the initial adoption of topical treatments._x000D_

_x000D_

The onychomycosis market is expected to experience robust growth in the upcoming years, with its size projected to reach $5.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This expansion during the forecast period can be attributed to several factors, including the escalating demand for combination therapies, the increasing adoption of teledermatology and remote monitoring, the ongoing development of AI-assisted diagnostic solutions, the broadening reach of hospital and retail pharmacy distribution, and a rise in investment for research into resistant fungal strains. Major trends anticipated in this period encompass the growing embrace of personalized antifungal therapies, the more frequent utilization of teledermatology for both diagnosis and monitoring, the expanding deployment of AI-based diagnostic tools specifically for nail infections, a heightened public awareness concerning nail health and hygiene, and the increasing innovation in combination drug and topical therapeutic approaches._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp_x000D_

_x000D_

What Drivers Are Supporting Technological Adoption In The Onychomycosis Market?_x000D_

The expanding population of diabetic patients is projected to fuel the expansion of the onychomycosis market. Diabetes, a chronic condition, arises from either inadequate insulin production by the pancreas or the body’s inefficient use of insulin. For individuals with diabetes, onychomycosis represents a frequent foot ailment, manageable through the prevention and control of its related complications. Consequently, the increasing occurrence of diabetes escalates the demand within the onychomycosis market. An illustrative example from June 2024 shows that the National Health Service, a UK-based government department, reported that in 2023, the NHS identified over half a million (549,000) more individuals in England susceptible to type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This figure marks a substantial increase from 3,065,825 in 2022, indicating a rise of nearly 20%. Thus, the increasing prevalence of diabetes is a key factor propelling the expansion of the onychomycosis market._x000D_

_x000D_

Which Segments Are Contributing To The Growth Of The Onychomycosis Market?_x000D_

The onychomycosis market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types_x000D_

2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections_x000D_

2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections_x000D_

3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients_x000D_

4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections_x000D_

5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis_x000D_

_x000D_

Which Competitive Trends Are Impacting The Structure Of The Onychomycosis Market?_x000D_

Leading firms within the onychomycosis market are creating novel product formulations to maintain their competitive standing. These advanced formulations facilitate progress in the onychomycosis market by enhancing treatment effectiveness and tackling particular difficulties linked to the ailment. As an example, in February 2024, Moberg Pharma AB, a Sweden-based pharmaceutical company, introduced MOB-015. This is a proprietary topical formulation of terbinafine, engineered to deliver therapeutic concentrations directly to the nail and nail bed, thereby reducing the systemic exposure risk associated with oral terbinafine. The product has garnered recommendations for national approval across 13 European countries and is sold in Sweden under the brand name Terclara. Its approval is supported by two Phase 3 trials, demonstrating that MOB-015 achieved superior mycological cure rates (76% in contrast to up to 42% for comparators) and a notably higher complete cure rate, without any reported serious adverse reactions._x000D_

_x000D_

Who Are The Top-Performing Companies In The Onychomycosis Market In Recent Years?_x000D_

Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report_x000D_

_x000D_

How Does The Onychomycosis Market Perform Across Major Global Regions?_x000D_

North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Onychomycosis Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12197&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Onychomycosis Market 2026, By The Business Research Company#_x000D_

_x000D_

Invasive Fungal Infections Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report_x000D_

_x000D_

Onychomycosis Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report_x000D_

_x000D_